Posted on July 23rd, 2015 by
Biotechnology company Amgen has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release.
Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in adults has a dismal prognosis, with only 35–40 percent of patients reaching a remission and a median overall survival of 4–6 months. Relapsed ALL is currently managed with stem cell transplantation and chemotherapy. Up to 40% of adults with ALL have a chromosomal abnormality known as Philadelphia chromosome positive.
Blincyto is a type of drug called anti-CD19 CAR T cell therapy. These drugs work by genetically modifying a patient’s T cells to express a chimeric antigen receptor (CAR) that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. Activation of the T cells in the immune system results in release of inflammatory proteins (cytokines) that fight the cancer. This specific technology is known as bispecific T cell engager (BiTE®), an innovative immunotherapy approach that helps the body’s immune system target cancer cells.
A Phase II trial has been evaluating Blincyto for effectiveness and safety in the treatment of patients with relapsed or refractory Ph+ ALL. The study included several cycles of Blincyto and a safety follow-up visit 30 days after patients completed treatment. The researchers continued to follow up with the patients every three months for up to 18 months to measure how long response to treatment lasted.
The results have been promising for Blincyto, as a significant number of patients’ disease has gone into remission. In addition, patients haven’t experienced any unexpected side effects.
“These top-line results are encouraging and support [Blincyto] as a potential treatment option for patients with relapsed or refractory Philadelphia chromosome-positive B-cell precursor ALL,” said According to Sean E. Harper, MD, executive vice president of Research and Development at Amgen. He added that they were hopeful that Blincyto would continue to produce good outcomes in patients with ALL.
Reference: Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia [press release]. Amgen website. Available at: https://www.amgen.com/media/media_pr_detail.jsp?year=2015&releaseID=2068505. Accessed July 20, 2015.
Copyright © 2015 CancerConnect. All Rights Reserved.
You must be logged-in to the site to post a comment.